Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8442978 | European Journal of Cancer | 2014 | 8 Pages |
Abstract
In dedifferentiated-SFT xenograft pazopanib induced a marginal antitumour activity, while regorafenib appeared the most active and promising agent. When administered in patients, pazopanib showed a modest activity in terms of tumour growth stabilisation, observed only in non-dedifferentiated cases.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
S. Stacchiotti, M. Tortoreto, G.G. Baldi, G. Grignani, A. Toss, G. Badalamenti, D. Cominetti, C. Morosi, A.P. Dei Tos, F. Festinese, E. Fumagalli, S. Provenzano, A. Gronchi, E. Pennacchioli, T. Negri, G.P. Dagrada, R.D. Spagnuolo, S. Pilotti,